Approved Study Database
Ref. No. | Scientific Title | Principal investigator |
---|---|---|
2020.032 | Health and Economic Impacts of Pre-Diabetes, Gestational Diabetes, Type 1 and Type 2 Diabetes in Hong Kong |
Dr. LUK Andrea On Yan 陸安欣 |
2020.438 | Delineating the metabolic architecture and response to anti-hyperglycaemic drug treatment in lean type 2 diabetes in Chinese | Dr. LUK Andrea On Yan |
2021.164 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with diabetic kidney disease. | Dr. LUK Andrea On Yan |
2022.404 | Healthcare utilisation and diseases in people with and those without diabetes in Hong Kong before and after COVID-19 pandemic | Prof Luk Andrea On Yan |
2022.148 | A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants with Mild to Moderate COVID-19 |
Dr. LUK Andrea On Yan 陸安欣 |
2023.314 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION | Prof. LUK Andrea On Yan |
2023.369 | Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Prof. LUK Andrea On Yan |
2021.501 | An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (BIIB098) in Chinese and Caucasian Adult Healthy Participants |
Dr. LUK Andrea On Yan 陸安欣 |
2012.482 | Descriptive study of clinical profile of Hong Kong diabetic population | Dr Luk Andrea On Yan |
2025.145 | Unravelling the pathogenicity of genetic variants in Wolfram Syndrome 1 gene in Chinese with young-onset diabetes |
Prof. LUK Andrea On Yan Andrea On Yan Luk |
2024.466 | A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants with Dyslipidaemia | Prof. LUK Andrea On Yan |
2024.159 | Implementation of a novel diabetes prevention programme in Hong Kong Chinese workforce at high risk of type 2 diabetes | Prof. LUK Andrea On Yan |
2022.634 | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus |
Prof. LUK Andrea On Yan 陸安欣 |
2014.385 | Best practice of holistic care: A case study approach | Dr. LUK Andrew Leung |
2025.103 | CQI Project: Enhancing Triage Assessment to Identify Patients Eligible for Nurse-Initiated Water Cooling for Burn Injuries | Mr. Luk Cheuk ho |
2007.365 | Longitudinal Change in Mental Competence for Treatment Decision in Chinese Older Adults with Congitive Impairment | Dr. LUK Daisy Nga Yan |
2023.237 | Clinical Characteristics and Outcomes of Infections due to carbapenem-resistant Enterobacterales in Hong Kong | Dr. LUK Fion Wing Lam |
2016.035 | Whole–body vibration training for residents in a care and attention home in Hong Kong and its influence on balance and mobility: a pilot study |
Ms. LUK Ho Yan 陸可欣 |
2008.401 | The Effect of Vital Signs Obtained at Prehospital and Emergency Department's Triage Station on Impatient Admission | Miss LUK Joies Ka Yan |
2009.414 | The effect of visual stimulation on the adult patient | Mr. LUK Kar Yiu |
2013.399 | Focused Ultrasound Screening for Precutaneous Dilatational Tracheostomy | Dr. LUK Leona Wing Kun |
2008.190 | Efficacy and Safety of Topical Photodynamic Therapy for Actinic Keratosis among Chinese Patients | Dr. LUK Nai Ming |
2011.493 | Hand eczema among inhabilitants of a public housing estate in Hong Kong: a self-administered questionnaire survey | Dr Luk Nai Ming |
2007.318 | Efficacy and Safety of Diphencyprone (DCP) in the Treatment of Extensive Alopecia Areata in Chinese Patient | Dr. LUK Nai Ming |
2009.437 | Efficacy of intralesional 5-fluorouracil in treatment of keloid scar : a randomized-control trial | Dr. LUK Nai Ming |
2013.347 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei | Dr. LUK Sally Wai Yin |
2014.406 | Effects of thromboelastography-guided transfusion algorithm versus standard clinical practice on post-operative bleeding and blood product use after cardiac surgery: a randomized, controlled trial | Dr. LUK Ting Hin |
2005.471 | Infliximab Induction Therapy for Moderate-to Severe Plaque-Type Psoriasis: An Open-Label, Single Arm Observational Study Evaluating the Efficacy of Use In Hong Kong Chinese Patients | Prof. LUK Tommy Nai Ming |
2023.551 | Impact of Injury Prevention Program on Ankle stability for ballet dancers | Ms. LUK Tsz Yan |
2005.264 | Psychological Distress, Quality of Life and Marital Relationship among Renal Patients Receiving Continuous Ambulatory Peritoneal Dialysis | Ms. LUK Yvonne Pik Shan |
2012.439 | Cross Sectional Survey on Advance Care Planning Acceptance & End of Life Care Preferences among community dwelling elderly with complex medical problems and their carers | Dr LUM Chor Ming |
2015.247 | Metformin-associated lactic acidosis requiring intensive care in regional hospitals in Hong Kong and predictive factors for mortality | Dr. LUN Chung Tat |
2020.411 | A one–year prospective study for intrapleural pressure for thoracentesis | Dr. LUN Chung Tat |
2021.245 | A COPD control questionnaire in a regional hospital during covid-19 pandemic | Dr. Lun Chung Tat |
2021.246 | an asthma control questionnaire in a regional hospital during covid-19 pandemic | Dr. LUN Chung Tat |
2018.407 | Prospective observational cohort study to assess the ability of mechanically-ventilated patients to press buttons on a smartphone application | Miss LUNG Catherine Chi Yan |
2008.417 | An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects with KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study) | Prof. MA Brigette |
2024.264 | A nurse-led lifestyle modification intervention for enhancing self-efficacy, illness perception, self-care management and steatosis grade among patients with metabolic dysfunction-associated steatotic liver disease: A pilot randomised controlled trial | Ms. MA Angel Cho Kan |
2023.300 | A nurse-led lifestyle modification intervention for enhancing self-efficacy, illness perception, self-care management and steatosis grade among patients with non-alcoholic fatty liver disease: A randomised controlled trial | Ms. MA Angel Cho Kan |
2023.693 | Perspectives on illness perception and self-management behaviours from patients with non-alcoholic fatty liver disease and healthcare professionals: An exploratory qualitative study | Ms. MA Angel Cho Kan |
2022.262 | A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers | Prof. MA Brigette |
2022.243 | daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) |
Prof. MA Brigette 馬碧如教授 |
2012.118 | Intensification of pre-operative therapy with multi-agent chemotherapy and concurrent chemoradiotherapy prior to total mesorectal excision surgery in patients with high risk rectal cancer | Prof. MA Brigette |
2010.604 | Multicenter Phase II Study of MK-2206 in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette |
2009.486 | A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer | Associate Professor Ma Brigette |
2012.192 | A pilot case-control study of second or third line treatment with cetuximab-containing chemotherapy in patients with metastatic colorectal cancer who were previously treated with cetuximab-based chemotherapy | Prof. MA Brigette |
2008.141 | A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer | Prof. MA Brigette |
2009.222 | A phase I dose escalation, multi-center, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies | Prof. Ma Brigette |
2009.223 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma | Professor Ma Brigette |
2008.091 | Multi-Centre International Study of Capecitabine + Bevacizumab as Adjuvant Treatment of Colorectal Cancer (QUASAR 2) | Associate Professor Ma Brigette |
Page 163 of 262.